Is the business good?
How good a business is VTRS?
Viatris earns −0.26% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−0.26%
Return on invested capital · cost of capital 9.0% · 9.3 points below what the capital costs: growth destroys value
- Operating margin
- −0.59%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q2 2026
- Share count, year on year
- −0.83%
Share count, year on year · flat: no meaningful dilution
- Gross margin
- 35%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −1.8% |
| FY2021 | −0.19% |
| FY2022 | 9.9% |
| FY2023 | 5.0% |
| FY2024 | 0.07% |
| FY2025 | −19% |
Details›
- Gross margin12 months to Q2 2026
- 35%
- Operating margin12 months to Q2 2026
- −0.59%
- Free cash flow margin
- 13%
- Revenue, trailing twelve months
- $14.7B
- Free cash flow, trailing twelve months
- $1.95B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −0.26%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #7 of 28 by Smart Score